GKOS Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of -12425.36%. Glaukos Corp.'s return on equity of -11.73% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Glaukos Corp. has a consensus price target of $127.31, signalling upside risk potential of 11.21%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 396.28%. Given that Perspective Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.668, which suggesting that the stock is 33.203% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Glaukos Corp.'s net income of -$16.2M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.82x versus 168.16x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of 6.19%. Glaukos Corp.'s return on equity of -11.73% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

Glaukos Corp. has a consensus price target of $127.31, signalling upside risk potential of 11.21%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 65.12%. Given that InfuSystem Holdings, Inc. has higher upside potential than Glaukos Corp., analysts believe InfuSystem Holdings, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.668, which suggesting that the stock is 33.203% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are larger than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. Glaukos Corp.'s net income of -$16.2M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 32.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.82x versus 1.29x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of -862.39%. Glaukos Corp.'s return on equity of -11.73% beat VolitionRX Ltd.'s return on equity of --.

Glaukos Corp. has a consensus price target of $127.31, signalling upside risk potential of 11.21%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 654.46%. Given that VolitionRX Ltd. has higher upside potential than Glaukos Corp., analysts believe VolitionRX Ltd. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.668, which suggesting that the stock is 33.203% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Glaukos Corp.'s net income of -$16.2M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.82x versus 19.98x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -12.16% compared to Glaukos Corp.'s net margin of 3.93%. Glaukos Corp.'s return on equity of -11.73% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Glaukos Corp. has a consensus price target of $127.31, signalling upside risk potential of 11.21%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 130.1%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Glaukos Corp., analysts believe Xtant Medical Holdings, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.668, which suggesting that the stock is 33.203% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $133.5M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Glaukos Corp.'s net income of -$16.2M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 63.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 13.82x versus 0.71x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.